{
  "authors": [
    {
      "author": "Georgio Medawar"
    },
    {
      "author": "Joseph Chahrouri"
    },
    {
      "author": "Rabih Said"
    }
  ],
  "doi": "10.1155/2019/2814504",
  "publication_date": "2019-07-03",
  "id": "EN112123",
  "url": "https://pubmed.ncbi.nlm.nih.gov/31263618",
  "source": "Case reports in rheumatology",
  "source_url": "",
  "licence": "CC BY",
  "language": "en",
  "type": "pubmed",
  "description": "",
  "text": "A 43-year-old female patient received tofacitinib for refractory rheumatoid arthritis (RA). Two years after 5â€‰mg bid daily dosing, the patient developed chronic myelogenous leukemia (CML), for which she received imatinib and tofacitinib was discontinued. She then remained in remission for rheumatoid arthritis and within the expected milestone outcome for her CML."
}